[Stitcher]

Aging Baby Boomers and Unmet Medical Needs Drive Alzheimer's and Parkinson's Diseases Market -- Drug Sales to Touch $11.5 Billion by 2010, According to New Report by Global Industry Analysts, Inc.

http://www.prweb.com/releases/alzhei...rweb541758.htm

World Alzheimer's and Parkinson's diseases market is projected to grow at a robust pace and is on course to reach US$11.5 billion by 2010. Ageing baby boomers and introduction of novel drugs represent the key growth drivers for the market.

San Jose, CA (PRWEB) July 25, 2007 -- Alzheimer's disease (AD) and Parkinson's disease (PD) are the two important segments in neurodegenerative disorders market, which is set to become the next big healthcare movement over the coming decades. These disorders are not only the instances of high-unmet medical needs but also significantly under diagnosed and vastly unjustified for various reasons. However, this unmet requirement offers substantial opportunities for next generation therapies. Though there is no curative medicine available at present, medications that provide partial relief from the symptoms have gained momentum in the recent past. The industry has crossed some milestones in recent years, although major breakthroughs are still in pipeline.

United States represents the largest as well as the fastest growing market, with a CAGR of 16%, as stated by Global Industry Analysts, Inc. Europe represents the second largest market, followed by Japan. Of the two broad product groups, anti-Alzheimer's drugs flaunt a much faster growth rate than anti-Parkinson's drugs, with a CAGR of 19.43% over the period 2000-2010. This stupendous growth rate has helped the anti-Alzheimer's drugs overtake anti-Parkinson's disease drugs as the largest product group. Low levels of competition from the generic space because of inadequate groups in the drug class continue to drive the AD market. Within anti-Alzheimer's drugs market, N-Methyl-D-Asparate receptor antagonists (NMDARA) represents the fastest segment, at over 40% CAGR. In the anti-Parkinson's disease drugs product group, dopamine agonists segment represents the largest and the fastest growing.

Alzheimer's and Parkinson's Diseases: A Global Strategic Business Report
Ageing baby boomers are expected to propel the global anti-AD medications market. The growing elder people in the society would always have impact on the healthcare markets particularly the drugs that are intended to treat risks associated with ageing. Since AD is an age related disorder, increasing baby boomers will always be a part of the growth engines of AD market. Additionally, the practice of combination therapy is likely to play an important role in the future treatment of AD and PD. The practice, already in wide spread use, is likely to continue, particularly in the severe or late stages of the diseases.

At present, only few drugs exist in the Alzheimer's and Parkinson's disease markets. The available products provide only symptomatic relief. However, novel drugs that are capable of slowing the progression of disease would eventually be launched in the market in the medium to long-term future. These therapies are in the final phases of clinical development and are expected to greatly influence the market. With about 18.5 million people suffering from these neurodegenerative diseases, the world market is anticipating some breakthrough products in future. The market provides mammoth opportunities for drug developers capable of producing drugs with substantial improvements over the currently available treatments.

Pharmaceutical majors including Pfizer/Eisai, Novartis, Shire/J&J, and Lundbeck/Forest Laboratories dominate the anti-Alzheimer's and anti-Parkinson's diseases drugs market. Pfizer/Eisai represents the leader in anti-Alzheimer's drugs with about 48% market share in 2006. Eisai and Pfizer co-promote Aricept in the US and major European markets. Other key market participants include Boehringer Ingelheim, Bristol-Myers Squibb Co., GlaxoSmithKline PLC, Merz Pharmaceuticals GMBH, and Roche.

The report titled "Alzheimer's and Parkinson's Diseases: A Global Strategic Business Report" published by Global Industry Analysts, Inc., provides a comprehensive review of market trends, market drivers, inhibitors, companies, products, future therapies, and competitive landscape. The report also provides statistical findings, market briefs, and concise summaries of research findings to help companies learn the truth behind market variables impacting business in the marketplace. The report has detailed analyses and coverage of the US, Canadian, Japanese, European, and Rest of World markets. Products segments analyzed include anti-Alzheimer's disease drugs (cholinesterase Inhibitors and NMDARA (N-methyl, D-Aspartate Receptor Antagonists)), and anti-Parkinson's disease drugs (dopaminergic agents, dopamine agonists, and other PD drugs).

For more details about this research report, please visit http://www.strategyr.com/MCP-1704.asp

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs more than 700 people worldwide and publishes more than 880 full-scale research reports each year. Additionally, the company also offers a range of more than 60,000 smaller research products including company reports, market trend reports and industry reports encompassing all major industries worldwide.